| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
6,799,115 |
$129,183,185 |
$19.00 |
28 Jun 2021 |
By Versant Venture Capital VI, L.P. |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
2,097,938 |
$39,860,822 |
$19.00 |
28 Jun 2021 |
By Versant Vantage I, L.P. |
| CRISPR Therapeutics AG |
Director |
Common Shares |
148,831 |
$9,302,369 |
$62.50 |
19 Jul 2021 |
Indirect |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
47,132 |
|
|
23 Jun 2021 |
Direct |
| Black Diamond Therapeutics, Inc. |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
15,000 |
|
|
18 Jun 2021 |
Direct |
| CRISPR Therapeutics AG |
Director |
Stock Option (Right to Buy) |
12,000 |
|
|
09 Jun 2022 |
Direct |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series A convertible preferred stock |
0 |
|
|
28 Jun 2021 |
By Versant Capital VI, L.P. |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
28 Jun 2021 |
By Versant Capital VI, L.P. |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
28 Jun 2021 |
By Versant Vantage I, L.P. |
| Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series C convertible preferred stock |
0 |
|
$2.96 |
28 Jun 2021 |
By Versant Vantage I, L.P. |